The Comprehensive in Vitro Proarrhythmia Assay (CiPA) initiative - Update on progress

Area of Science:

• Cardiovascular pharmacology
• Drug safety assessment
• Regulatory science

Background:

• Current ICH S7B and E14 guidelines focus on hERG block and QT prolongation, potentially hindering drug development.
• An expanded understanding of torsadogenic mechanisms necessitates a new approach to proarrhythmia risk assessment.

Purpose of the Study:

• To establish a new paradigm for assessing proarrhythmic risk using advanced technologies.
• To develop and validate predominantly nonclinical assays to predict clinical proarrhythmia risk.
• To eliminate the need for the thorough-QT study in drug development.

Main Methods:

• Evaluating drug effects on human ventricular ionic channel currents in heterologous systems.
• Utilizing in silico integration of cellular electrophysiologic effects.
• Assessing drug effects on fully integrated biological systems, including stem-cell-derived cardiac myocytes and human ECG.

Main Results:

• The CiPA initiative is progressing towards its validation target date.
• Development of a multi-disciplinary, international collaboration involving regulatory bodies and scientific organizations.
• Focus on a broader understanding of torsadogenic mechanisms beyond hERG block.

Conclusions:

• The CiPA initiative aims to provide a more precise prediction of clinical proarrhythmia risk.
• This new paradigm is expected to streamline drug development and enhance patient safety.
• The project involves significant collaboration between regulatory agencies, industry, and academia.